JP2013519728A - カリウムチャンネルモジュレーターとしてのヘテロ環 - Google Patents

カリウムチャンネルモジュレーターとしてのヘテロ環 Download PDF

Info

Publication number
JP2013519728A
JP2013519728A JP2012553927A JP2012553927A JP2013519728A JP 2013519728 A JP2013519728 A JP 2013519728A JP 2012553927 A JP2012553927 A JP 2012553927A JP 2012553927 A JP2012553927 A JP 2012553927A JP 2013519728 A JP2013519728 A JP 2013519728A
Authority
JP
Japan
Prior art keywords
alkyl
fluoro
pyridin
pyridyl
trifluoromethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2012553927A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013519728A5 (enExample
Inventor
クリストス,トーマス・ユージン
アマート,ジョージ・エス
アトキンソン,ロバート・エヌ
バロッリ,マリア・グラシエラ
ウォルフ−グーベイア,リリ・アン
スト,マーク・ジェイ
Original Assignee
アイカジェン, インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アイカジェン, インコーポレイテッド filed Critical アイカジェン, インコーポレイテッド
Publication of JP2013519728A publication Critical patent/JP2013519728A/ja
Publication of JP2013519728A5 publication Critical patent/JP2013519728A5/ja
Pending legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50Pyridazines; Hydrogenated pyridazines
    • A61K31/5025Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/10Drugs for disorders of the urinary system of the bladder
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/16Otologicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychology (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
JP2012553927A 2010-02-16 2011-02-02 カリウムチャンネルモジュレーターとしてのヘテロ環 Pending JP2013519728A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12/706,574 US8431608B2 (en) 2007-08-17 2010-02-16 Heterocycles as potassium channel modulators
US12/706,574 2010-02-16
PCT/US2011/023444 WO2011102964A1 (en) 2010-02-16 2011-02-02 Heterocycles as potassium channel modulators

Publications (2)

Publication Number Publication Date
JP2013519728A true JP2013519728A (ja) 2013-05-30
JP2013519728A5 JP2013519728A5 (enExample) 2014-03-06

Family

ID=43734000

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012553927A Pending JP2013519728A (ja) 2010-02-16 2011-02-02 カリウムチャンネルモジュレーターとしてのヘテロ環

Country Status (5)

Country Link
US (2) US8431608B2 (enExample)
EP (1) EP2536718A1 (enExample)
JP (1) JP2013519728A (enExample)
CA (1) CA2788783C (enExample)
WO (1) WO2011102964A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017523209A (ja) * 2014-08-06 2017-08-17 ファイザー・インク イミダゾピリダジン化合物
KR20180072704A (ko) * 2015-10-23 2018-06-29 나비토르 파마슈티칼스 인코포레이티드 세스트린-gator2 상호작용의 조절제 및 이의 용도

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2400604T3 (es) * 2007-08-17 2013-04-11 Icagen, Inc. Heterociclos como moduladores del canal de potasio
UY36636A (es) * 2015-04-21 2016-11-30 Glaxosmithkline Ip Dev Ltd Compuesto derivado de butanamida con actividad antiparasitaria
WO2017223474A1 (en) 2016-06-23 2017-12-28 St. Jude Children's Research Hospital Small molecule modulators of pantothenate kinases
US10183972B2 (en) 2016-07-14 2019-01-22 University Of South Florida BK channel-modulating peptides and their use
AR110922A1 (es) * 2017-02-06 2019-05-15 Gilead Sciences Inc Compuestos inhibidores del vih
TWI776886B (zh) 2017-04-26 2022-09-11 美商奈維特製藥公司 Sestrin-gator2交互作用之調節劑及其用途
WO2019051197A1 (en) * 2017-09-07 2019-03-14 Board Of Regents Of The University Of Nebraska TRPC5 INHIBITORS AND METHODS OF USE
MX2020006754A (es) 2017-12-27 2021-01-29 St Jude Childrens Res Hospital Inc Moduladores de molécula pequeña de pantotenato-cinasas.
JP7644002B2 (ja) 2018-10-24 2025-03-11 ナビター ファーマシューティカルズ, インコーポレイテッド 多形化合物およびその使用
WO2020198526A2 (en) * 2019-03-27 2020-10-01 St. Jude Children's Research Hospital Small molecule modulators of pank
EP4051259A4 (en) 2019-11-01 2023-11-22 Navitor Pharmaceuticals, Inc. METHOD OF TREATMENT USING A MMOC1 MODULATOR
WO2023133256A1 (en) * 2022-01-07 2023-07-13 Biohaven Therapeutics Ltd. Pyrazolo[1,5-a]pyridin-2,3-yl amides as kv7 channel activators
CN122029154A (zh) * 2023-09-28 2026-05-12 深圳市康哲生物科技有限公司 杂芳基衍生物及其应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009026254A1 (en) * 2007-08-17 2009-02-26 Icagen, Inc. Heterocycles as potassium channel modulators

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3701780A (en) 1970-09-18 1972-10-31 Merck & Co Inc Imidazo(1,2-a)pyridines
US4096264A (en) 1975-12-09 1978-06-20 Merck & Co., Inc. Certain substituted imidazo [1,2-a] pyridines
GB8719368D0 (en) 1987-08-15 1987-09-23 Wellcome Found Heterocyclic compounds
JPH0168375U (enExample) 1987-10-23 1989-05-02
MY125533A (en) 1999-12-06 2006-08-30 Bristol Myers Squibb Co Heterocyclic dihydropyrimidine compounds
CA2311483A1 (en) 2000-06-12 2001-12-12 Gregory N Beatch IMIDAZO [1,2-A] PYRIDINIC ETHERS AND USES THEREOF
AU2002232439A1 (en) 2000-11-29 2002-06-11 Glaxo Group Limited Benzimidazole derivatives useful as tie-2 and/or vegfr-2 inhibitors
US6939874B2 (en) 2001-08-22 2005-09-06 Amgen Inc. Substituted pyrimidinyl derivatives and methods of use
US7632866B2 (en) 2002-10-21 2009-12-15 Ramot At Tel Aviv University Derivatives of N-phenylanthranilic acid and 2-benzimidazolone as potassium channel and/or neuron activity modulators
MXPA05004890A (es) 2002-11-07 2005-07-22 Merck & Co Inc Derivados de fenilalanina como inhibidores de dipeptidilpeptidasa para el tratamiento o prevencion de diabetes.
US7563788B2 (en) 2004-03-19 2009-07-21 Pfizer Inc. Substituted Imidazo[1,2-a]pyridines as Antibacterial Agents
TW200633990A (en) 2004-11-18 2006-10-01 Takeda Pharmaceuticals Co Amide compound
US20070161645A1 (en) 2005-11-02 2007-07-12 Targegen, Inc. Thiazole inhibitors targeting resistant kinase mutations
PE20070978A1 (es) 2006-02-14 2007-11-15 Novartis Ag COMPUESTOS HETEROCICLICOS COMO INHIBIDORES DE FOSFATIDILINOSITOL 3-QUINASAS (PI3Ks)
KR20070115502A (ko) 2006-06-02 2007-12-06 파크시스템스 주식회사 주사 탐침 현미경 및 이를 이용한 측정방법
BRPI0714665A2 (pt) 2006-08-04 2012-03-13 Takeda Pharmaceutical Company Limited Composto, pró-droga, agente farmacêutico, e, método para a profilaxia ou tratamento do câncer
US20100029619A1 (en) 2006-08-04 2010-02-04 Takeda Pharmaceutical Company Limted Fused heterocyclic compound
AU2007292924A1 (en) 2006-09-07 2008-03-13 Biogen Idec Ma Inc. IRAK modulators for treating an inflammatory condition, cell proliferative disorder, immune disorder
PE20091268A1 (es) 2007-12-19 2009-09-19 Amgen Inc Derivados heterociclicos como inhibidores de pi3 quinasa
WO2009136663A1 (en) 2008-05-08 2009-11-12 Takeda Pharmaceutical Company Limited Fused heterocyclic derivatives and use thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009026254A1 (en) * 2007-08-17 2009-02-26 Icagen, Inc. Heterocycles as potassium channel modulators

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017523209A (ja) * 2014-08-06 2017-08-17 ファイザー・インク イミダゾピリダジン化合物
KR20180072704A (ko) * 2015-10-23 2018-06-29 나비토르 파마슈티칼스 인코포레이티드 세스트린-gator2 상호작용의 조절제 및 이의 용도
JP2021050208A (ja) * 2015-10-23 2021-04-01 ナビター ファーマシューティカルズ, インコーポレイテッド セストリン−gator2相互作用のモジュレーターおよびその使用
JP7449843B2 (ja) 2015-10-23 2024-03-14 ナビター ファーマシューティカルズ, インコーポレイテッド セストリン-gator2相互作用のモジュレーターおよびその使用
KR102708250B1 (ko) 2015-10-23 2024-09-23 나비토르 파마슈티칼스 인코포레이티드 세스트린-gator2 상호작용의 조절제 및 이의 용도

Also Published As

Publication number Publication date
WO2011102964A1 (en) 2011-08-25
US20100240663A1 (en) 2010-09-23
CA2788783A1 (en) 2011-08-25
EP2536718A1 (en) 2012-12-26
CA2788783C (en) 2014-06-03
US9018208B2 (en) 2015-04-28
US8431608B2 (en) 2013-04-30
US20130143889A1 (en) 2013-06-06

Similar Documents

Publication Publication Date Title
JP5463287B2 (ja) カリウムチャネル調節物質としての複素環
US8431608B2 (en) Heterocycles as potassium channel modulators
JP7677983B2 (ja) Pgdh阻害剤、およびその作製と使用の方法
JP2024516317A (ja) Shp2リン酸化酵素阻害剤の調製と応用
AU2019374812B2 (en) Pyridazinone compounds and uses thereof
JP2020147607A (ja) 横隔膜機能を向上させるための方法
KR20240133737A (ko) Nlrp3 인플라마좀 억제제 및 이의 적용
JP2018104456A (ja) キナーゼ調節のための化合物と方法、及びそのための適応
CN104394869A (zh) 用作沉默调节蛋白调节剂的取代的双环氮杂杂环化合物和类似物
KR20190015756A (ko) Shp2 억제제로서 유용한 신규한 헤테로환형 유도체
CA2692761A1 (en) Fused heteroaryl pyridyl and phenyl benzenesulfonamides as ccr2 modulators for the treament of inflammation
JP2013519724A (ja) Nadphオキシダーゼ阻害剤としてのピラゾロピペリジン誘導体
JP2007505143A (ja) カリウム・チャネル・モジュレーターとしての縮合環式複素環
JP2021529185A (ja) 心臓サルコメア阻害剤
TW201623310A (zh) 用於誘發軟骨生成之化合物及組合物
CA2958671A1 (en) Imidazopyridazine compounds and their use
JP2019537592A (ja) ムスカリン性アセチルコリンレセプターm4のポジティブアロステリック調節因子
CN103102349B (zh) 蛋白激酶抑制剂及其组合物和用途
JP2019537581A (ja) ムスカリン性アセチルコリンレセプターm4のポジティブアロステリック調節因子
JP2019537590A (ja) ムスカリン性アセチルコリンレセプターm4のポジティブアロステリック調節因子
JP2021505581A (ja) ムスカリン性アセチルコリンレセプターm4のポジティブアロステリック調節因子
CN111433212A (zh) 毒蕈碱型乙酰胆碱受体m4的正向别构调节剂
CA3197199A1 (en) Compounds and compositions for the treatment of cryptosporidiosis
BRPI0614272A2 (pt) derivados de imidazopiridinas como ligantes de receptores canabinóides
CN121002030A (zh) 作为毒蕈碱型乙酰胆碱受体m4的正向别构调节剂的噻唑并吡啶衍生物

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140120

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20140120

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20141204

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20141208

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150219

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20150907